European Court Rules Mannose as a Medicine

The European Court of Justice (ECJ) has determined that mannose, a monosaccharide, should be classified as a medicinal product rather than a medical device. This ruling has significant implications for the regulation and marketing of products containing mannose, particularly those aimed at treating urinary tract infections (UTIs).

The classification of a product as a medicine or a medical device is crucial, as it determines the regulatory requirements for approval and sale. Medicinal products are subject to stringent testing and approval processes due to their potential pharmacological effects, while medical devices typically require less rigorous scrutiny.

The case arose from a legal dispute involving the pharmaceutical company Klosterfrau and the Association of Social Competition (VSW). Klosterfrau previously marketed Femannose®, a product intended for the prevention and treatment of UTIs, which contained both D-mannose and cranberry extract. However, since October 2017, the company has offered Femannose N, a formulation without cranberry extract.

The VSW challenged Klosterfrau's classification of Femannose as a medical device, asserting that the product should be considered a medicinal product requiring approval. The Regional Court of Cologne ruled in favor of the VSW, stating that the products in question exhibit a pharmacological effect due to the presence of D-mannose.

This ruling was upheld by the Higher Regional Court of Cologne, which confirmed that D-mannose meets the criteria outlined in the European Medicines Agency's guidelines for pharmaceutical substances. The legal proceedings ultimately led to a preliminary ruling request from the Federal Court of Justice (BGH) to the ECJ on whether mannose possesses pharmacological properties, thereby necessitating classification as a medicine.

The ECJ's decision emphasizes a broad interpretation of medicinal product regulations, suggesting that products with any significant pharmacological effect should be treated under the stricter medicinal product framework. Consequently, this ruling will require Klosterfrau to adhere to the stringent regulatory processes associated with marketing a medicinal product.

The implications of this ruling extend beyond Klosterfrau, as it sets a precedent for how similar products containing mannose and other active ingredients may be regulated across Europe. Manufacturers of dietary supplements and other health products may need to reassess their formulations and marketing strategies in light of this decision to ensure compliance with medicinal product legislation.